Monday, March 9, 2020 Drug-Delivery Technology Leads to Sustained HIV Antibody Production Illustration of a virus delivering genetic material into a cell. Credit: National Human Genome Research Institute A new approach to direct the body to make a specific antibody against HIV led to sustained production of that antibody for more than a year among participants in a NIAID clinical trial. This drug-delivery technology uses a harmless virus to deliver an antibody gene into human cells, enabling the body to generate the antibody over an extended time. With further development, such a strategy could be applied to prevent and treat a wide variety of infectious diseases. Researchers reported the findings today at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107